Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments

被引：6
|
作者：
Roeb, Elke [1 ,2 ]
Geier, Andreas [3 ]
机构：
[1] Justus Liebig Univ, Dept Gastroenterol, Giessen, Germany
[2] Univ Hosp Giessen, Giessen, Germany
[3] Univ Hosp Wurzburg, Div Hepatol, Wurzburg, Germany
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2019年 / 57卷 / 04期
关键词：
non alcoholic fatty liver disease; steato hepatitis; liver fibrosis; FATTY LIVER-DISEASE; FIBROSIS; ELASTOGRAPHY; BIOPSY; NAFLD; METAANALYSIS; DIAGNOSIS; RISK;
D O I：
10.1055/a-0784-8877
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Nonalcoholic fatty liver disease (NAFLD) includes nonalcoholic fatty liver (NAFL), nonalcoholic steato hepatitis (NASH) and NASH cirrhosis. NAFLD is the leading cause of liver diseases in the Western world (Central Europe, United States). The NAFLD incidence increases because of increasing type 2 diabetes and obesity. This article reviews the scientific findings of epidemiology, diagnostic, and therapeutic management of NAFLD. Lifestyle modifications (low-caloric Mediterranean diet and exercise training) to reduce weight are a major factor in the treatment of NAFLD. Pharmacological therapies may be useful in patients with NASH and fibrosis as well as nonresponders to lifestyle modifications. Currently, however, no pharmacological substances are approved for the indication NASH.
引用
收藏
页码：508 / 517
页数：10
相关论文
共 50 条
  • [41] Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis
    Polyzos, Stergios A.
    Kang, Eun Seok
    Boutari, Chrysoula
    Rhee, Eun-Jung
    Mantzoros, Christos S.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2020, 111
  • [42] A short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH)
    Roberts, Stuart K.
    Majeed, Ammar
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2021, 25 (10) : 889 - 895
  • [43] GPR91 antagonism: A novel approach for the treatment of nonalcoholic steatohepatitis (NASH)
    Umrani, Dhananjay
    Bhuniya, Debnath
    Tambe, Suhas
    Shaikh, Nadim
    Thakkar, Mahesh
    Patel, Jigneshkumar S.
    Parekar, Nilkanth V.
    De, Siddhartha
    Athvankar, Sonali
    Joshi, Dhananjay
    Dharamshi, Anjana
    Bhadra, Sonali
    Kini, Mahima
    Kandikere, Vishwottam
    Madgula, Vamsi
    Tambe, Ashwini
    Mahajan, Vallabh
    Fawzi, Ahmad
    Kulkarni, B. A.
    Mookhtiar, Kasim
    HEPATOLOGY, 2016, 64 : 793A - 793A
  • [44] Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)
    Duarte, Sebastiao M. B.
    Stefano, Jose Tadeu
    Oliveira, Claudia P.
    ANNALS OF HEPATOLOGY, 2019, 18 (03) : 416 - 421
  • [45] Current treatments in nonalcoholic steatohepatitis
    Torres D.M.
    Harrison S.A.
    Current Treatment Options in Gastroenterology, 2007, 10 (6) : 425 - 434
  • [46] Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Spengler, Erin K.
    Loomba, Rohit
    MAYO CLINIC PROCEEDINGS, 2015, 90 (09) : 1233 - 1246
  • [47] Current knowledge of nonalcoholic steatohepatitis
    Ricote, GC
    Monzón, CG
    MEDICINA CLINICA, 2003, 121 (03): : 102 - 108
  • [48] THE GROWING BURDEN OF NONALCOHOLIC STEATOHEPATITIS (NASH) IN THE UNITED STATES
    Younossi, Zobair M.
    Paik, James M.
    Henry, Linda
    Yang, Joe
    Fernandes, Gail
    Stepanova, Maria
    Nader, Fatema
    GASTROENTEROLOGY, 2022, 162 (07) : S1133 - S1134
  • [49] Systematic review of fibrosis progression in nonalcoholic steatohepatitis (NASH)
    Argo, Curtis K.
    Northup, Patrick G.
    Caldwell, Stephen H.
    HEPATOLOGY, 2006, 44 (04) : 650A - 651A
  • [50] Potential biomarkers in the fibrosis progression of nonalcoholic steatohepatitis (NASH)
    Z. Wang
    Z. Zhao
    Y. Xia
    Z. Cai
    C. Wang
    Y. Shen
    R. Liu
    H. Qin
    J. Jia
    G. Yuan
    Journal of Endocrinological Investigation, 2022, 45 : 1379 - 1392
12345